Products
Pre-Made Albinterferon Alfa- 2B Biosimilar, Fusion Protein targeting IFNAR1 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-725
Pre-Made Albinterferon Alfa- 2B Biosimilar, Fusion Protein targeting IFNAR1 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Chronic hepatitis C (CHC) is one of the most common causes of chronic liver disease. Albinterferon alfa-2b (alb-IFN) is an 85.7-kilodalton protein consisting of recombinant human interferon (IFN) alfa-2b genetically fused to recombinant human albumin. alb-IFN retains the antiviral properties of IFN alfa, with significant suppression of HCV RNA in the replicon system.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-725-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-725-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-725-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-725-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Albinterferon Alfa- 2B Biosimilar, Fusion Protein targeting IFNAR1 fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC |
| INN Name | Albinterferon Alfa- 2B |
| Target | IFNAR1 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - ALB (albumin, human serum albumin, HSA) 25-609 - IFNA2 (interferon alpha 2) *b (R46,H57) 24-188 |
| VD LC | Fusion - ALB (albumin, human serum albumin, HSA) 25-609 - IFNA2 (interferon alpha 2) *b (R46,H57) 24-188 |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Novartis Pharmaceuticals Corp. (East Hanover NJ USA) / Human Genome Sciences Inc. (HGSI) (Rockville MD USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
Facebook
LinkedIn
Twitter
